Eurogentec was founded in 1985 as a spin-off of the University of Liège (Belgium). Its mission is to design and deliver reliable and innovative services and products for the Life-Science community. As a leading supplier for genomic and proteomic research, Eurogentec is able to offer its customers integrated solutions, whether they use DNA, probes, antibodies, peptides and/or proteins as research or diagnostic tools.
We offer oligonucleotide synthesis with a large range of modifications, oligonucleotides for In Vitro Diagnostic (IVD), design and synthesis of siRNA from the low quantity for screening to gram quantities for in vivo applications, Real-Time PCR products, DNA MicroArray services and a wide range of kits and consumables. We have a small chemical synthesis facility to design, produce and evaluate special monomers and reagents for use in the synthesis of non-standard oligonucleotides and peptides.
Eurogentec has also a large experience in antibody production (>2500 polyclonal productions per year since more than 10 years, production for diagnostic partners, ELISA developments). On this basis, Eurogentec has developed technical know-how in the design of peptides for antipeptide production and in the preparation of protein/Antibodies array with a large animal facility (capacity over 2000 animals – state-of-the art and 100% compliant versus any international guidelines), and the capacity to produce hundreds of peptides per week.
Since 2003, Eurogentec provides also Custom Peptide-, Antibody- and Protein- Microarray solutions for academic and industrial customers, ranging from peptide-, antibody- and/or protein selection and synthesis, manufacture of the arrays to the complete profiling service including protein extraction and solubilization, labeling, binding and data analysis.
Eurogentec also offers research and development services for the diagnostic and the biopharmaceutical industry (GMP).
Eurogentec has developed a sales and marketing network all over the world :
- Europe: more than 20 sales representatives and 4 distributors
- Asia: the joint venture Nippon-EGT in Japan and the joint venture RB-EGT in Singapore
- America: Eurogentec North America, Inc., with its collaboration with VWR and acquisition of the Oligo synthesis Division of EPOCH BIOSCIENCES Inc. in San Diego with 5 sales representatives
The market of Eurogentec are the public research laboratories and institutes, the R&D laboratories of the pharmaceutical industries and the diagnostic industries.